Anti-allodynic effects of systemic inhibitors of Acid-Sensing Ion Channels 1 (ASIC1) against acute and chronic migraine in rodents

Clément Verkest, Émilie Piquet, Sylvie Diochot, Mélodie Dauvois, Michel Lanteri-Minet, Eric Lingueglia, Anne Baron

To cite this version:

Clément Verkest, Émilie Piquet, Sylvie Diochot, Mélodie Dauvois, Michel Lanteri-Minet, et al.. Anti-allodynic effects of systemic inhibitors of Acid-Sensing Ion Channels 1 (ASIC1) against acute and chronic migraine in rodents. British Journal of Pharmacology, Wiley, 2018, Molecular Pharmacology of GPCRs, 175 (21), pp.4154-4166. 10.1111/bph.14462. hal-02267117

HAL Id: hal-02267117
https://hal.archives-ouvertes.fr/hal-02267117
Submitted on 20 Aug 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Anti-allodynic effects of systemic inhibitors of Acid-Sensing Ion Channels 1 (ASIC1) against acute and chronic migraine in rodents
Dear Editor,

Please find enclosed a manuscript entitled "Anti-allodynic effects of systemic inhibitors of Acid-Sensing Ion Channels 1 (ASIC1) against acute and chronic migraine in rodents" by C. Verkest, E. Piquet, S. Diochot, M. Dauvois, M. Lanteri-Minet, E Lingueglia and A Baron, that we are submitting for publication in British Journal of Pharmacology.

Acid-Sensing Ion Channels (ASICs) are voltage-insensitive cation channels activated by extracellular acidosis, which have been proposed to be important pain detectors of sensory neurons in the orofacial area. This was based in large part on the use of amiloride, a non-specific ASIC blocker, which showed beneficial effects in animal models of migraine and in patients in a pilot open clinical study.

In this paper, we focused on cutaneous allodynia, a hallmark of migraine especially in its chronic form, which is highly disabling, difficult to treat, and affect both cephalic and extra-cephalic regions. We explored the involvement of the ASIC1-subtype in these symptoms by combining amiloride and mambalgin-1, a peptide specifically blocking ASIC1-containing channels. We show that i.v. injection of these compounds reverse acute and chronic cutaneous allodynia not only in extra-cephalic territories as usually assessed, but also in cephalic ones, in a rodent model of migraine induced by systemic injection of the nitric oxide donor isosorbide dinitrate (ISDN). The anti-allodynic effects were not altered in ASIC1a-knock-out mice, suggesting a prevailing contribution of sensory neuron-specific ASIC1b-containing channels. They are comparable to the ones of the anti-migraine drug sumatriptan and of the preventive drug topiramate on acute and chronic allodynia, respectively. Mambalgin-1 also exerts a prophylactic effect on the development of chronic allodynia upon daily inter-attack injection. Our findings therefore support a role for peripheral ASIC1-containing channels in migraine cutaneous allodynia as well as in its chronification, and demonstrate the therapeutic potential of systemic ASIC1-specific inhibitors for both acute and prophylactic treatment of migraine and headaches.
CV, EP, MLM, EL and AB designed research; CV, EP, SD, MD, AB performed research and SD, CV, MLM, EL and AB wrote the paper. All authors have read and approved the manuscript. No financial or other relationship might lead to a conflict of interest.

Thank you for the attention you will be giving to this paper,

Sincerely yours,

Drs. Anne Baron and Eric Lingueglia
Anti-allodynic effects of systemic inhibitors of Acid-Sensing Ion Channels 1 (ASIC1) against acute and chronic migraine in rodents

**Running title:** ASIC1 channel inhibitors against acute and chronic migraine

Clément Verkest¹,²,³ Emilie Piquet³,⁴ Sylvie Diochot¹,²,³ Mélodie Dauvois¹, Michel Lanteri-Minet³,⁴,⁵ Eric Lingueglia¹,²,³, *, #, Anne Baron¹,²,³, *, #

¹: Université Côte d’Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, France.
²: LabEx Ion Channel Science and Therapeutics, Valbonne, France.
³: FHU InovPain, Université Côte d'Azur, Nice, France.
⁴: CHU Nice, Hopital Cimiez, Département d’évaluation et de traitement de la douleur, Nice, France.
⁵: Inserm/UdA, U1107, Neuro-Dol, Trigeminal Pain and Migraine, Université d’Auvergne, France.
* E.L. and A.B. contributed equally to this work.
# Corresponding authors.

**Author contributions**
CV, EP, MLM, EL and AB designed research; CV, EP, SD, MD, AB performed research and SD, CV, MLM, EL and AB wrote the paper.

**Word count** (Intro +Results +Discussion: 3940)

**Acknowledgments**
We thank R. Dallel for initial help with the ISDN-induced model in rats and discussion, D. Servent for providing synthetic mambalgin-1, E. Deval, P. Inquimbert, J. Noël, M. Salinas, M. Chafai, S. Marra and T. Besson for helpful discussions, M. Lazdunski for his support, V. Friend for expert technical assistance, and V. Berthieux for secretarial assistance. This work was supported by CNRS, Inserm, the Fondation pour la Recherche Medicale (DEQ20110421309) and the Agence Nationale de la Recherche (ANR-13-BSV4-0009, ANR-17-CE18-0019, and ANR-11-LABX-0015-01).
Conflict of interest statement

The authors declare no conflict of interest.

Abstract

Background and purpose

Acid-Sensing Ion Channels (ASICs) are neuronal proton sensors emerging as potential therapeutic targets in pain of the orofacial region. Amiloride, a non-specific ASIC blocker, has been shown to exert beneficial effects in animal models of migraine and in patients. We explored the involvement of the ASIC1-subtype in cutaneous allodynia, a hallmark of migraine affecting cephalic and extra-cephalic regions in about 70% of migrainers.

Experimental approach

We investigated the effects on cephalic and extra-cephalic mechanical sensitivity of systemic injections of amiloride and mambalgin-1, a specific inhibitor of ASIC1a- and ASIC1b-containing channels, in a rodent model of acute and chronic migraine induced by intraperitoneal injections of isosorbide dinitrate.

Key results

Intravenous injection of these inhibitors reversed attack-like cephalic and extra-cephalic acute cutaneous mechanical allodynia in rats, inducing a delay in the subsequent establishment of chronic allodynia. Mambalgin-1 or amiloride also reversed established chronic allodynia. This effect was not altered in ASIC1a-knock-out mice, suggesting a prevailing contribution of sensory neuron-specific ASIC1b-containing channels. Mambalgin-1 anti-allodynic effects are comparable to the ones of the anti-migraine drug sumatriptan and of the preventive drug topiramate on acute and chronic allodynia, respectively. A single daily inter-attack injection of mambalgin-1 also had a significant preventive effect on allodynia chronification.

Conclusions and Implications

These data support the involvement of ASIC1-containing channels, with possibly a major role of the peripheral ASIC1b subtype, in migraine cutaneous allodynia as well as in its chronification. They highlight the therapeutic potential of ASIC1 inhibitors in migraine for both acute and prophylactic treatment.
Abbreviations

ASIC: Acid-sensing Ion channel
Mamb-1: mambalgin-1
CSD: cortical spreading depression
TG: trigeminal
NO: nitric oxide
ISDN: isosorbide dinitrate
TNC: trigeminal nucleus caudalis
CGRP: calcitonin gene-related peptide
i.v.: intravenous
i.pl.: intraplantar
i.p.: intraperitoneal
5-HT: serotonin or 5-hydroxy tryptamine
KO: knock-out

Keywords:
ASIC, mambalgin, migraine, allodynia, amiloride
Introduction

Migraine is a major contributor to public ill health (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Vos T, 2016) with still poorly understood pathogenetic mechanisms (Goadsby et al., 2017) possibly including extracellular acidification. Cortical spreading depression (CSD), considered to be the neurophysiological correlate of migraine aura, could activate and sensitize trigeminal (TG) meningeal nociceptors (Karatas et al., 2013) through local release of extracellular compounds (K⁺, ATP, nitric oxyde…), dural sterile inflammation and ischemia associated with extracellular acidification also involving mast cells degranulation (Levy, 2009; Rozniecki et al., 1999). Subsequent sensitization of central pathways would cause cephalic and extra-cephalic cutaneous allodynia (Boyer et al., 2014; Burstein et al., 2010; Burstein et al., 2015; Edelmayer et al., 2009) reported by 70% of migrainers during migraine attacks (Lipton et al., 2008). Per year, approximately 2.5% of episodic migrainers become chronic migrainers, with at least 15 days of headache per month (Bigal et al., 2008; Lipton et al., 2015), showing acute cutaneous alldynia during attacks but also interictal alldynia between them (Lovati et al., 2008; Zappaterra et al., 2011). Cutaneous alldynia is now considered as a marker and a risk factor for chronic migraine (Benatto et al., 2017; Louter et al., 2013), chronic migraine onset being increased by 30% among episodic migrainers, and chronic migraine persistence being increased by 15% in chronic migrainers (Scher et al., 2017).

Preclinical migraine models in rodents are based on human observations. Nitric oxide (NO) donors such as nitroglycerin (NTG) (Ashina et al., 2013) and nitrate-based drugs with slower pharmacokinetics like isosorbide dinitrate (ISDN) used in the treatment of cardiovascular disease (Hansen et al., 2017; Iversen et al., 1992; Olesen et al., 2015), trigger a delayed-migraine attack associated with cutaneous facial and extra-facial alldynia (de Tommaso et al., 2004; Thomsen et al., 1996). In rodents, NO donors evoke elevated CGRP blood levels, meningeal inflammation, photo- and phonophobia, sensitization of central neurons of the trigeminal nucleus caudalis (TNC), cephalic and extra-cephalic alldynia, as well as spontaneous facial pain. The efficiency of clinically relevant treatments like sumatriptan, CGRP antagonists and antibodies, anti-inflammatory drugs, or prophylactic drugs like propranolol and topiramate further support the relevance of these animal models of migraine (Bates et al., 2010; Farkas et al., 2016; Goadsby et al., 2017; Harris et al., 2017; Jansen-Olesen et al., 2013; Pradhan et al., 2014; Schytz et al., 2017). Effects of systemic ISDN injections were recently described in rats, with a facilitation of C-fiber-evoked responses in 50% of second-order central neurons (Dallel et al., 2017; Flores Ramos et al., 2017), leading to cutaneous pain sensitization.
Acid-Sensing Ion Channels (ASICs) are voltage-insensitive cation channels activated by extracellular acidosis (ASIC1-3) (Waldmann et al., 1997) and lipids (ASIC3) (Marra et al., 2016). They are widely expressed throughout the peripheral and central nervous system where they have been implicated in various pathophysiological processes including pain (Deval et al., 2015). Most subunits are expressed in TG neurons, where ASIC1- and ASIC3-containing channels can contribute to activation of meningeal afferents (Yan et al., 2011; Yan et al., 2013) and in migraine pathophysiology (Dussor, 2015). ASIC1a and 2a are expressed by second-order neurons of the TNC (Cho et al., 2015), and brain ASIC1a-containing channels have been implicated in CSD (Holland et al., 2012).

Peptide toxins from animal venoms specifically targeting different ASIC subtypes have been instrumental to reveal their roles in pain (Baron et al., 2013; Bohlen et al., 2011; Deval et al., 2008; Mazzuca et al., 2007), including mambalgins that exert potent analgesic effects against acute, inflammatory and neuropathic pain through specific inhibition of ASIC1a- and/or ASIC1b-containing channels (Diochot et al., 2016; Diochot et al., 2012). Using mambalgin-1 (Mamb-1) in combination with amiloride, a non-specific ASICs blocker, we explored here the involvement of ASIC1-containing channels in mechanical cephalic and extra-cephalic cutaneous allodynia in the ISDN-induced model of migraine in rodents.

**Methods**

**Animals**

Experiments were performed on male Sprague Dawley rats (Janvier Labs) weighting 250 to 400g (mean weight: 306 ± 12g, 6 to 9 weeks old), and on male C57BL/6J wild-type (Charles River Laboratories) and ASIC1a-knock-out mice (Wemmie et al., 2002) of 7-13 week-old weighting 20-25g. Animals were housed in a 12 hours light-dark cycle with food and water available ad libitum. Animal procedures were approved by the Institutional Local Ethical Committee and authorized the French Ministry of Research according to the European Union regulations and the Directive 2010/63/EU (Agreements C061525 and 01550.03). Animals were sacrificed at experimental end points by CO2 euthanasia.

**Drugs and in vivo injections**

Synthetic Mamb-1, showing the same pharmacological activity than native peptide, was purchased from Synprosis/Provepep (Fuveau, France), Smartox (Saint Martin d’Hères, France), or obtained from Commissariat à l’Energie Atomique, iBiTecS, Service d’Ingénierie Moléculaire des
Protéines (Gif sur Yvette, France) (Mourier et al., 2016). The biological activity of all synthetic Mambô1 batches was validated on heterologously expressed recombinant ASIC channels.

Mambô1 was dissolved in vehicle solution containing NaCl 0.9% and bovine serum albumin 0.05% to prevent non specific toxin adsorption. For intravenous (i.v.) injections in rats, Mambô1 (11.3 nmole/kg, i.e., 200 µl of 16.5 µM for a 300g rat), amiloride hydrochloride hydrate (10 mg/kg, i.e., 200 µl of 56 mM for a 300g rat, Sigma Aldrich), topiramate (30 mg/kg, i.e., 500 µl of 18 mg/ml for a 300g rat, Selleckchem), all dissolved in vehicle solution, or sumatriptan succinate (10 mg/kg i.e., 250 µl of injectable 12 mg/ml solution for a 300g rat, Imiject®, GlaxoSmithKline) were injected in the caudal vein of conscious rats (restrained in a cylinder) with a 30G needle. For intraplantar subcutaneous (i.pl.) injections, Mambô1 (6.7 nmole/kg, i.e., 50 µl of 41 µM for a 300g rat) was injected in the left hindpaw of conscious rats with a 26G needle. For mice, Mambô1 (13.6 nmole/kg, i.e., 200 µl of 1.7 µM for a 25g mouse) dissolved in vehicle solution was i.v. injected in the caudal vein of conscious mice (restrained in a cylinder) with a 30G needle.

**Thermal and mechanical sensitivity measurements**

Thermal sensitivity was assessed using the Hargreaves plantar test (Ugo Basile, Italy). Unrestrained rats were placed in individual plastic boxes on a glass floor. The withdrawal latency (s) of the rat hindpaw exposed to an infrared source (intensity of 190 ±1 mW/cm²) was measured in triplicate with at least 1min between two stimulations, and the mean latency was calculated. A cut-off period of 20s was used to avoid potential tissue damage. Rats were trained 2 days before experiments. To test the effect of Mambô1, thermal sensitivity was measured every 15 minutes before (basal value) and during two hours after Mambô1 or vehicle injection.

The face mechanical sensitivity was measured using calibrated von Frey filaments (Bioseb, France). Unrestrained rats placed in individual plastic boxes on top of a wire surface boxes were trained over one week to stimulation on the periorbital area, following a progressive protocol, starting with non-noxious filaments during the first 3 days of training. The face withdrawal force threshold (g) was determined by the filament evoking at least 3 responses over five trials, starting with lower force filaments. To test the effect of ISDN, the face mechanical sensitivity was measured every 15 minutes before (basal value) and during three hours after intraperitoneal (i.p.) injection. To test the effect of Mambô1 and other compounds, face mechanical sensitivity was measured every 15 minutes before (basal value) and during two hours after compound or vehicle injection.

The hindpaw mechanical sensitivity was evaluated with a dynamic plantar aesthesiometer (Ugo Basile, Italy). Unrestrained rats were placed in individual plastic boxes on top of a wire surface.
The rat hindpaw was submitted to a force ramp up to 30 g during 20 s, the paw withdrawal force threshold (g) was measured in triplicates, and the mean force was calculated. Rats were trained 2 days before experiments. To test the effect of ISDN, the hindpaw mechanical sensitivity was measured every 15 minutes before (basal value) and during three hours after intraperitoneal (i.p.) injection. To test the effect of Mamb-1 and other drugs, the hindpaw mechanical sensitivity was measured every 15 minutes before (basal value) and during two hours after injection. For mice, the same procedure was used, except that the mice hindpaw was submitted to a force ramp up to 7.5 g during of 10 s, and that the hindpaw mechanical sensitivity was measured every 30 minutes.

**Pain models**

Local inflammation was induced by *i.pl.* injection in the left hindpaw of 100 µl of 2% carrageenan (Sigma-Aldrich) with a 25G needle. Thermal and mechanical sensitivity were measured before (basal values) and 3 hours after the carrageenan injection to measure heat hyperalgesia and mechanical allodynia induced by inflammation (control values). Effects of drugs were followed by measurements every 15 min during 2 hours after their injection.

The rat model of NO-induced migraine was induced by intraperitoneal (i.p.) injection of ISDN (Risordan®, Sanofi) at 10mg/kg. The cephalic and hindpaw extra-cephalic mechanical sensitivities were measured simultaneously on the same rat. The attack-like mechanical allodynia induced by a single ISDN injection was followed for 3 hours after injection. Chronic mechanical allodynia was induced by a single daily injection of ISDN during 4 days. Cephalic and extra-cephalic mechanical sensitivity were measured each day before the ISDN *i.p.* injection. Drugs were tested on chronic mechanical allodynia on the 5th day and effects were followed every 15 min during 2 hours after injection. This model has been transposed to mice according to the same protocol, except that only the hindpaw extra-cephalic mechanical sensitivity was measured.

**Data analysis**

The power calculation was performed with an alpha value of 0.05 and a power of 0.8 with G*Power software, to calculate the minimum sample size per group needed depending on the expected variability of measurements (which differs between behavioral tests) and the type of statistical test to be used. For example, for rat experiments, the minimal calculated sample size was 8 with effect sizes between 1.6 and 1.1. As most of our behavioral experiments and pharmacological treatments were not previously tested, and to anticipate the possible occurrence of non-respondent animals to pre-required treatments by carrageenan or ISDN, we set our usual minimal experimental sample size to 9. This “n” value refers to independent values and not includes
technical replicates (replicates were used to calculate a mean individual value). Control (or vehicle treated) animals and test animals were randomized within experimental days. Data are presented as mean values ± standard error of the mean (SEM). Data analysis and statistics were performed with Microcal Origin 6.0 and GraphPad Prism 4 softwares by two independent experimenters. The normality of data distribution was tested by KS normality test, D’Agostino & Pearson omnibus normality test and Shapiro-Wilk normality test, and parametric or non parametric tests were chosen for normal or non normal data distribution, respectively. Non parametric tests were used when the number of animals per experimental group was less than 10, because the results of normality tests were not fully reliable in these conditions. The statistical difference between two different experimental groups was analyzed by the parametric unpaired Student’s t-test or by the non parametric Mann-Whitney test. The statistical difference between more than two different experimental groups was assessed by the parametric one-way analysis of variance (Anova) followed by a Tukey post-test, or by the non parametric Kruskall Wallis test followed by a Dunns post-test. For data within the same experimental group, a parametric paired Student’s t-test or a non parametric Wilcoxon matched pair test were used. For behavioral experiments, kinetics of effects were shown, along with cumulative effect over 2 hours after injection of drugs, or over 3 hours after ISDN injection, calculated as Area Under the Curve (AUC, g x min for mechanical sensitivity, or s x min for thermal sensitivity) subtracted from the control value for each animal.

Results

Anti-allodynic effects of i.v. mambalign-1 against inflammatory pain in rats

Mambalgins exert analgesic effects in mice upon different routes of administration (i.pl., i.v., i.t.) and against different types of pain, including inflammatory pain (Diochot et al., 2016; Diochot et al., 2012). However, their effects in rats were never tested. Before using the ISDN-induced model of migraine for simultaneous measurements of cephalic and extra-cephalic mechanical sensitivity, we first determined the effect of Mamb-1 in inflammatory pain in rats. Three hours after i.pl. injection of 2% carrageenan in the hindpaw, mechanical allodynia was observed, with a decrease in withdrawal threshold force from 18.4 ± 0.5 down to 9.2 ± 0.2g (Fig. 1A), as well as heat hyperalgesia, with a decrease in withdrawal latency from 9.0 ± 0.3 down to 4.3 ± 0.2s (Fig. 1B). Intravenous injection of Mamb-1 induced a complete and sustained reversal of the inflammatory-induced mechanical allodynia (Fig 1A, 19.1 ± 0.8g after 45 minutes), as well as a complete reversion of the inflammatory-induced heat hyperalgesia (Fig. 1B, 8.7 ± 0.5s, after 45 minutes). Local i.pl. injection of Mamb-1 in the rat inflamed hindpaw also resulted in a complete and
sustained reversal of the inflammatory-induced mechanical allodynia (Fig. 1C) and heat hyperalgesia (Fig. 1D). The kinetics and total effects of Mamb-1 were comparable between *i.v.* and *i.pl.* injections (Fig. 1C-F). Interestingly, *i.pl.* and *i.v.* injections of Mamb-1 had no effect on hindpaw mechanical pain threshold in naive rats (Suppl. Fig. 1).

These data indicate that *i.v.* or *i.pl.* Mamb-1 exert anti-allodynic effects on inflammatory pain in rats, comparable to the effects we already described in mice that were mainly peripheral and caused by the inhibition of ASIC1b-containing channels (Diochot *et al.*, 2016).

**Effect of *i.v.* mambalgin-1 and amiloride on acute cutaneous mechanical allodynia in the ISDN-induced model of migraine**

The ISDN-induced chronic migraine model was developed recently in rats (Dallel *et al.*, 2017; Flores Ramos *et al.*, 2017), related to the chronic NTG-induced model first developed in mice (Pradhan *et al.*, 2014). One *i.p.* injection of ISDN (10 mg/kg) induces mechanical allodynia mimicking that is occurring during migraine attack, with a decrease in cephalic and extra-cephalic mechanical sensitivity. The facial and hindpaw withdrawal force thresholds reached their minimal values after 1.5 hours (3.6 ± 0.2 from a basal control value of 7.8 ± 0.2g; and 12.9 ± 0.4 from a basal control value of 17.5 ± 0.2g, respectively) that were maintained for at least 3 hours, whereas *i.p.* injections of saline were without effect (Suppl. Fig. 2A, B, black symbols, left panels). Twenty four hours later, alldyna was still not fully reversed, and one ISDN injection per day during four days resulted in the progressive development of a chronic basal mechanical allodynia (from 7.8 ± 0.2 to 2.4 ± 0.2g on the face, and from 17.5 ± 0.2 to 10.3 ± 0.2g on the paw; Suppl. Fig. 2C, D), which was correlated with a progressive decrease in the ISDN-induced attack-like cephalic and extra-cephalic total effect on acute cutaneous allodynia, the last injection inducing no more significant effect (Suppl. Fig. 2A, B, right panels). The chronic basal mechanical allodynia persisted several days after the last ISDN injection, and a nearly total reversion was observed 15 days after the end of ISDN treatment (Suppl. Fig. 2C, D).

The effect of *i.v.* Mamb-1 on the attack-like acute mechanical allodynia induced by the first ISDN injection was tested. Mamb-1 was injected after the full development of acute alldyna (*i.e.*, 105 min after ISDN *i.p.* injection). Mamb-1 induced a full reversal of facial mechanical allodynia (Fig. 2A), the withdrawal force increasing from the allodynic value of 3.3 ± 0.5 up to 7.6 ± 0.4g one hour after the *i.v.* injection, which is not significantly different from the baseline (8.0 ± 0.3g). On the same animals, Mamb-1 only induced a partial reversal of the hindpaw mechanical allodynia, the withdrawal force increasing from the alldynic value of 11.2 ± 0.5 up to 14.0 ± 1.3g one hour
after the *i.v.* injection (Fig. 2B). These effects were sustained for at least 2 hours. The anti-allodynic effect of *i.v.* Mamb-1, which significantly reduced the total effects of the first injection of ISDN on cutaneous allodynia, induced a one-day shift in the development of chronic allodynia induced by subsequent daily *i.p.* injections of ISDN in both cephalic and extra-cephalic territories, without any change in the maximal basal allodynia measured on the last day (Fig. 2C, D). This supports, as suggested in humans, a causality link between occurrence of attack-like mechanical allodynia and the development of chronic allodynia.

The effect of *i.v.* Mamb-1 on ISDN-induced attack-like mechanical allodynia was compared with the one of amiloride, a well-known non-selective inhibitor of ASICs, and also with the one of acute migraine therapy sumatriptan, a 5-HT1B/1D receptor agonist. Amiloride or sumatriptan succinate, both *i.v.* injected in the same conditions as Mamb-1, also exerted an anti-allodynic effect. Amiloride induced a full reversion of face mechanical allodynia (Fig. 3A) and a partial but significant reversion of hindpaw allodynia (Fig. 3B), similar to the sustained Mamb-1 effects. As expected from its therapeutical effect, and as previously described in mice models of migraine (Bates *et al.*, 2010; Pradhan *et al.*, 2014), sumatriptan also showed sustained anti-allodynic properties, with a partial reversion of both facial (Fig. 3A) and hindpaw (Fig. 3B) allodynia.

All together, these data show that systemic *i.v.* Mamb-1 and amiloride efficiently reverse the ISDN-induced, attack-like acute cephalic, and to a lesser extent extra-cephalic, mechanical cutaneous allodynia, with a similar, and even higher, potency than sumatriptan.

**Effects of *i.v.* mambalgin-1 and amiloride on the maximal chronic cutaneous mechanical allodynia in the ISDN-induced model of migraine**

When Mamb-1 was injected one day after the last ISDN injection (*i.e.*, on the fifth day), it fully reversed the maximal chronic facial mechanical allodynia (Fig. 4A), increasing the facial withdrawal force from 3.0 ± 0.4 up to 9.6 ± 2.1g after one hour, a value similar to baseline (8.6 ± 0.9g). Mamb-1 also partially reversed the maximal chronic hindpaw mechanical allodynia (Fig. 4B), increasing the paw withdrawal force from 9.8 ± 0.2 up to 15.0 ± 1.1g after one hour, which is significantly different from vehicle as well as from baseline (18.0 ± 0.2g). Amiloride also showed similar anti-allodynic effects (Fig. 4A, B). Both compounds were as potent as topiramate, a clinically used preventive drug against migraine, whereas sumatriptan used in acute migraine therapy was ineffective (Fig. 4C-F), as previously described (Pradhan *et al.*, 2014). Local *i.pl.*
injection of Mambô1, which was able to reverse inflammatory-induced mechanical paw allodynia
(Fig 1C), was without effect on ISDN-induced chronic paw mechanical allodynia (Suppl Fig. 3)
showing that the local inhibition of ASICs in sensory neurons of the paw was not involved in the
anti-allodynic effect of Mambô1 on the paw ISDN-induced allodynia, contrary to the effects on
inflammatory pain. Interestingly, the absence of effect of i.pl. injection of Mambô1 on chronic facial
ISDN-induced allodynia, confirmed that the effect of the peptide upon i.pl. injection remains local
without important systemic diffusion through blood.

These data show that systemic i.v. Mambô1 and amiloride efficiently reverse the maximal
chronic cephalic and extra-cephalic chronic cutaneous mechanical alldynia with a potency similar
to topiramate.

**Preventive effect of i.v. mambalgin-1 treatment on the development of chronic cutaneous
mechanical alldynia in the ISDN-induced migraine model**

Mambô1 was able to reverse the maximal chronic cutaneous allodynia induced by four days
of ISDN injections. We tested next the effects of one daily i.v. injection of Mambô1 for four days,
between ISDN-induced attacks, and their consequences on the development of chronic alldynia.

In good agreement with the data showing no effect of i.v. injection of Mambô1 on basal paw
mechanical threshold in naive rats (Suppl. Fig. 1), the i.v. injection of Mambô1 30 minutes before
the first i.p. injection of ISDN did not change the basal face and paw mechanical sensitivities
(Fig. 5A, B, black symbols), nor the attack-like effect of ISDN, with the maximal alldynia
reaching 5.3 ± 0.5 from the basal level of 8.2 ± 0.2g on the face, and 13.7 ± 0.3 from a basal level of
18.5 ± 0.2g on the paw (Fig. 5A, B black symbols) after two hours, which was not significantly
different from vehicle injected rats (Fig. 5C, D, black symbols). A basal alldynia appeared the day
after (i.e., on day 2; Fig 5E, F) that was reversed by Mambô1 i.v. injected 30 minutes before the
second ISDN injection (Fig. 5A, B red symbols), whereas vehicle was without effect (Fig. 5C, D,
red symbols). On day 3, the basal cutaneous alldynia was significantly less pronounced in Mambô-
1-treated compared to vehicle-treated rats, reaching 5.1 ± 0.4g on the face and 14.7 ± 0.3g on the
paw, and 2.9 ± 0.4g on the face and 13.4 ± 0.2g on the paw, respectively (Fig. 5E, F). Repeated i.v.
injection of Mambô1 on day 3 and 4 finally led to a significant reduction in the maximal chronic
alldynia on day 5, i.e., 24 hours after the last ISDN injection, reaching 4.7 ± 0.3g on face and 13.8
± 0.5g on paw, compared to 1.9 ± 0.3g and 11.5 ± 0.4g, respectively, on vehicle-treated rats
Consequently, an ISDN-induced attack-like increase in allodynia was still observed in Mamb-1-treated rats on the fourth day (Fig. 5A, B, blue symbols), but not in vehicle-treated rats already close to the maximal alldynic level (Fig. 5C, D, blue symbols).

Our results show that daily inter-attack i.v. injection of Mamb-1 was able to significantly reduce the chronic alldynia that develops upon injection of ISDN for several days, especially on facial territory.

The anti-allodynic effect of i.v. mambalgin-1 in the ISDN-induced chronic migraine model is still present in ASIC1a knock-out mice

Since Mamb-1 inhibits ASIC1-containing channels (i.e., comprising either ASIC1a- and/or ASIC1b subunits), the contribution of ASIC1a to its anti-allodynic effects in the ISDN-induced chronic migraine model was tested on hindpaw mechanical sensitivity in ASIC1a-knock-out (KO) mice. In wild-type mice, the first i.p. injection of ISDN induced an acute paw alldynia, with the withdrawal force decreasing from 4.1 ± 0.1 down to 3.0 ± 0.1g two hours after the ISDN injection (Fig. 6A, black symbols). Alldynia was not fully reversed the next day, and one ISDN injection per day during four days resulted, like in rats, in the progressive development of a chronic mechanical alldynia correlated with a progressive decrease in the daily ISDN-induced attack, leading to the absence of effect of the fourth ISDN injection (Fig. 6A, blue symbols). On day 5 (i.e., 24 hours after the last ISDN injection), the maximal chronic alldynia reaches 2.7 ± 0.1 from the control (day 1) value of 4.1 ± 0.1g and was reversed towards control mechanical sensitivity by an i.v. injection of Mamb-1 (Fig. 6B). Interestingly, the reversion of chronic paw alldynia was complete in mice, whereas only partial in rats. The same experiments have been done in ASIC1a-KO mice and showed no difference with wild-type animals either in the ISDN-induced acute attack-like alldynia (at day 1 and at day 4) (Fig. 6C), nor in the development of chronic alldynia (reaching 2.6 ± 0.1 from the control day 1 value of 4.1 ± 0.1g, not significantly different from wild-type mice with Mann Whitney non parametric test) and in the anti-allodynic effects of i.v. Mamb-1 on the maximal chronic alldynia (Fig. 6D).

These data show that ASIC1a is not needed for the anti-allodynic effects of Mamb-1 nor for establishment of the ISDN-induced migraine model in mice. They also indicate that ISDN has a similar effect in mice than in rats after repetitive daily injections with the establishment of a
maximal chronic basal allodynia, which is consistent with what was previously described with nitroglycerin as the NO-donor (Pradhan et al., 2014).

**Discussion**

In this study, we show the anti-allodynic effects of intravenous ASIC1 inhibitors in a rodent model of migraine induced by daily *i.p.* injection of ISDN, a long lasting NO-donor. Mambalgin-1 and amiloride reverse cephalic and extra-cephalic cutaneous allodynia when *i.v.* injected during the acute attack evoked by one ISDN injection, with an effect similar to the one of sumatriptan, and cause a delay in the establishment of chronic alldynia induced by subsequent ISDN injections. ASIC1 inhibitors are also able to reverse the maximal cephalic and extra-cephalic chronic alldynia when *i.v.* injected after the four injections of ISDN, with an effect similar to the one of topiramate. Daily inter-attack *i.v.* injection of Mamb-1 is able to significantly reduce maximal cutaneous alldynia, thus exerting a preventive effect on the establishment of chronic alldynia.

**Involvement of peripheral ASIC1-containing channels in migraine-induced cutaneous allodynia and in its chronification.**

The contribution of ASIC1 channels in acute and chronic cutaneous alldynia in the ISDN-induced migraine model is strongly supported by the similar anti-allodynic effects of amiloride, a well described non-selective inhibitor of ASICs, and Mamb-1, a specific inhibitor of ASIC1-containing channels (Diochot et al., 2012). Mamb-1, contrary to amiloride, does not block the epithelial sodium channel involved in blood pressure regulation (Suppl. Fig. 4), making unlikely a significant indirect vascular contribution of these compounds in the ISDN-induced migraine model. In rodents, Mamb-1 only inhibits ASIC1a- and ASIC1b-containing channels, with ASIC1a expressed in both central and sensory neurons, and ASIC1b exclusively expressed in sensory neurons. We have previously shown that the central effects of Mamb-1 are totally lost in ASIC1a-KO mice (Diochot et al., 2016; Diochot et al., 2012). ASIC1a is not necessary to the anti-allodynic effect of *i.v.* Mamb-1 in the ISDN-induced migraine model. This precludes a major contribution of central ASIC1a-containing channels and supports a peripheral effect involving ASIC1b specifically expressed in sensory neurons, although a direct demonstration is hampered by the lack of ASIC1b-KO mice. However, native ASICs are composed of three identical or different subunits, and the contribution of peripheral ASIC1a subunit in wild-type animals cannot be ruled out, for instance within heteromeric channels made of ASIC1a and ASIC1b. Our results are also in good agreement with our previous data in mice showing a major role for peripheral ASIC1b-containing channels in the analgesic effect of *i.v.* mambalgin-1 on inflammatory pain (Diochot et al., 2016).
Peripheral ASIC1-containing channels in TG sensory fibers could be therefore involved in the pathophysiology of migraine, possibly correlated with meningeal extracellular acidification as one of the initiating events. Our results support the involvement of ASICs that can be activated by NO-induced extracellular acidification (through mast cells degranulation) and further stimulated by inflammatory mediators and associated transduction pathways. ASIC1- and ASIC3-containing channels were proposed as important pain detectors in sensory neurons of the orofoacial area (Fu et al., 2016) notably in the dura mater. About 80% of rat dural afferents trigger action potentials at pH6.0, 50% at pH7.0 and 30% at pH7.1. As a consequence, an acidic pH6.0 solution applied on dura mater generates sustained cephalic and extra-cephalic allodynia, which is maximal after 2 hours and inhibited by amiloride but not TRPV1 antagonists, supporting the involvement of ASICs activation in migraine-related behavior in vivo (Yan et al., 2011; Yan et al., 2013). ASIC3-containing channels have been proposed to be involved in these effects (Yan et al., 2013), as well as in the potentiating effects of inflammatory factors, but our data now also support the involvement of ASIC1-containing channels (presumably ASIC1b) since Mamb-1 does not inhibit ASIC3-containing channels (Diochot et al., 2012). In addition to ASIC3-containing channels, which are expressed in 80% of pH-sensitive dural fibers (Yan et al., 2013), the ASIC1a, ASIC1b and ASIC2 subunits were also present in TG neurons (Cho et al., 2015; Flegel et al., 2015; Fu et al., 2016; Manteniotis et al., 2013), and data obtained with ASIC1a-KO mice support the involvement of ASIC1-like currents in TG ganglion in orofacial inflammatory pain (Fu et al., 2016). Transcriptome analyses recently showed higher expression of ASIC1 in TG versus lumbar DRG neurons (Lopes et al., 2017). Another interesting point concerns the NO potentiation of ASICs in heterologous systems as well as in rat sensory neurons (Cadiou et al., 2007), with transient effects on ASIC1a, ASIC2a and ASIC3 currents, but an irreversible effect on rat ASIC1b current that could also contribute to the role of ASIC1b in the ISDN-induced model.

Inhibition of peripheral ASIC1-containing channels in TG afferents by systemic Mamb-1 and amiloride could thus participate in the analgesic effects seen in the ISDN-induced rat migraine model. Local i.pl. injection of Mamb-1 in the paw was not able to reverse ISDN-induced chronic paw mechanical allodynia, whereas it fully reversed the inflammatory-induced one. The systemic extra-cephalic, anti-allodynic effect of Mamb-1 would thus not be due to local inhibition of peripheral sensory ASIC1-containing channels in the paw, but would rather be a consequence of the reversion of cephalic ISDN-induced allodynia through inhibition of ASIC1-containing channels in TG sensory fibers. Peripheral sensitization of the TG sensory neurons leads to secondary central sensitization of the second order neurons of the TNC and upper cervical spinal cord (C1-C2), thus
causing subsequent cephalic allodynia, whereas extra-cephalic allodynia would reflect the further extension of central sensitization to upper central pain relays (like thalamus), particularly during the settlement of a chronic state (Boyer et al., 2014). Highly diffusible NO is also able to directly exert central effects, with modulation of medullary dorsal horn neurons (Flores Ramos et al., 2017), TNC neurons, and VPM thalamus neurons (Goadsby et al., 2017), thus amplifying cutaneous pain sensitization and leading to NO-induced delayed migraine headache. The anti-allodynic and anti-chronification effects of ASIC1 inhibitors are weaker on extra-cephalic than on cephalic allodynia in our experiments in rats. Similar incomplete effects were reported for amiloride in another rat migraine model with a direct dural acidic stimulation (Yan et al., 2013) and in a mice NTG-induced model of chronic migraine (Tipton et al., 2015), cephalic alldynia being not assessed in both studies. The complete reversibility of cephalic alldynia by ASIC1 inhibitors that we observed would suggest that sensitization of the TNC and the upper cervical dorsal horn could depend directly on the activity of ASIC1-containing channels expressed in TG sensory neurons, whereas extra-cephalic alldynia would be partially independent of them, involving ASIC-independent effects of NO on paw sensory fibers (Ferrari et al., 2016) or central mechanisms independent of TG fibers activation (Bernstein et al., 2012).

Systemic ASIC1 blockers against migraine

Treatment of migraine, and particularly chronic migraine, remains challenging, and most of the therapeutic drugs are non specific, sometimes inefficient, with numerous side effects and contraindications (Schytz et al., 2017; Serrano et al., 2015). Cutaneous alldynia in chronic migraine is associated with inadequate outcomes for any anti-migraine medication (Lipton et al., 2017). Furthermore, a significant proportion of chronic migraine cases are due to anti-migraine medication abuse or misuse (Bigal et al., 2009; Lipton et al., 2015), highlighting the need of new medications, including new prophylactic approaches to prevent the chronification process.

We show that i.v. amiloride and mambalgin-1 both exert anti-allodynic effects against acute and chronic cutaneous allodynia in the ISDN-induced migraine model, not only in extra-cephalic territories as usually assessed but also in cephalic ones, and that i.v. mambalgin-1 is able to exert a prophylactic effect on the development of chronic alldynia. This supports systemic ASIC1 inhibitors as new potential therapeutic leads against migraine and headaches and this is in good agreement with data showing that a preventive daily therapy with i.p. amiloride in mice partially reduce acute NTG-induced as well as chronic basal mechanical paw hypersensitivity (Tipton et al., 2015). A pilot open clinical study has also shown that systemic treatment with amiloride reduced
aura and headache symptoms in four of seven patients with intractable aura (Holland et al., 2012). Drawback of amiloride, which is used in humans as a diuretic and antihypertensive, is a poor specificity, and our data suggest that more specific ASIC1 blockers like mambalgin-1 could also be used 1) to relieve migraine attack, with benefits on subsequent chronification, 2) to relieve established chronic allodynia, and 3) as a preventive treatment against chronification.

References


Benatto, MT, Florencio, LL, Carvalho, GF, Dach, F, Bigal, ME, Chaves, TC et al. (2017) Cutaneous allodynia is more frequent in chronic migraine, and its presence and severity seems to be more associated with the duration of the disease. *Arq Neuropsiquiatr* 75(3): 153-159.


**Figure legends**

**Fig. 1: Reversion of inflammation-induced paw mechanical allodynia and heat hyperalgesia by intravenous and local intraplantar injections of mambalgin-1 in rats.**  

A, C - Full reversion by *i.v.* (A) and by *i.pl.* (C) Mamb-1 (11.3 and 6.7 nmole/kg, respectively) of paw inflammatory mechanical allodynia (carrageenan 2%, 3h). Paw mechanical withdrawal force (g), mean ± SEM, n=9, * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to vehicle.  

B, D - Full reversion by *i.v.* (B) and *i.pl.* (D) Mamb-1 of paw inflammatory heat hyperalgesia (carrageenan 2%, 3h). Paw withdrawal latency (s), mean ± SEM, n=9, * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to vehicle, # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to non inflamed basal value.  

E, F - Total effect of *i.v.* and of *i.pl.* Mamb-1 on paw mechanical withdrawal force calculated as the Area Under Curve (AUC) (E) and on heat paw withdrawal latency (F) calculated as the AUC during 2 hours after the injection. Mean ± SEM, n=9, respectively. * p<0.05, ** p<0.01, *** p<0.001, ns not significant compared to vehicle with Mann Whitney non parametric test.

**Fig. 2: Reversion of ISDN-induced, attack-like cephalic and extra-cephalic acute mechanical allodynia by an intravenous injection of mambalgin-1.**  

A, B - Left panels - Kinetics of the anti-alldynic effect on face (A) and paw (B) mechanical withdrawal thresholds (g) of an *i.v.* injection of Mamb-1 (11.3 nmole/kg) 105 minutes after the *i.p.* injection of ISDN in rats. Mean ± SEM, n = 9. * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to vehicle; # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to control value before ISDN injection.  

Right panels - Total effect of *i.v.* Mamb-1 (or vehicle) on face (A) and paw (B) withdrawal force calculated as the Area Under Curve (AUC) during 2 hours after the *i.v.* injection. Mean ± SEM, n = 9. * p<0.05, ** p<0.01, *** p<0.001 compared to vehicle with Mann Whitney non parametric test.  

C, D - One *i.v.* injection of Mamb-1 (11.3 nmole/kg) after the first ISDN injection, as shown in A and B, induces a delay in the subsequent settlement of ISDN-induced chronic alldynia induced by three more daily ISDN injections. Basal face (C) and paw (D) mechanical withdrawal force (g) measured before each daily ISDN injection and the day after the last ISDN injection (day 5). Mean ± SEM, n = 9. * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to vehicle; # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to control before the first ISDN injection.
Fig. 3: Comparison of the anti-allodynic effects of mambalgin-1, amiloride and sumatriptan on ISDN-induced, attack-like cephalic and extra-cephalic acute mechanical allodynia.

**A, B Left panels** - Kinetics of the analgesic effects on face (A) and paw (B) mechanical withdrawal force (g) of amiloride (10 mg/kg) and sumatriptan succinate (Imiject©, 10 mg/kg) i.v. injected 105 minutes after the injection of ISDN measured on the same rats. Mean ± SEM, n = 9. * p<0.05, ** p<0.01, *** p<0.001 with non-parametric Kruskal-Wallis and Dunn’s post hoc tests compared to vehicle; # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to control value before ISDN injection. For clarity, only vehicle (same data as in Fig. 2A, B) but not Mamb-1 is shown. **Right panels** - Total effect of vehicle, Mamb-1, amiloride and sumatriptan on face (A) and paw (B) withdrawal force calculated as the Area Under Curve (AUC) during 2 hours after injection. Mean ± SEM, n = 9. * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to vehicle; # p<0.05, ## p<0.01, ### p<0.001 with Mann Whitney non parametric test compared to Mamb-1.

Fig. 4: Reversion of ISDN-induced maximal cephalic and extra-cephalic chronic mechanical allodynia by an intravenous injection of mambalgin-1.

**A-D** - Kinetics of the anti-allodynic effect of Mamb-1 (11.3 nmole/kg), amiloride (10 mg/kg), sumatriptan succinate (Imiject©, 10 mg/kg) and topiramate (30 mg/kg), i.v. injected one day after the last ISDN injection (i.e., on day 5) on face (A, C) and paw (B, D) mechanical withdrawal force (g) in rats. The basal mechanical withdrawal force (g) was measured before each daily ISDN injection (left side of the y axe), showing the chronification process of cutaneous allodynia day after day. For clarity, kinetics were split into two graphs, sharing the same data for vehicle. Mean ± SEM, n = 9 except with topiramate (n=11). * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to vehicle; # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to control value before the first ISDN injection (day 1). **E, F** - Total effect on face (E) and paw (F) withdrawal force calculated as the Area Under Curve (AUC) during 2 hours after the i.v. injection for each rat. Mean ± SEM, n = 9. * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to vehicle; # p<0.05, ## p<0.01, ### p<0.001 with Mann Whitney non parametric test compared to Mamb-1.
Fig. 5: Preventive effect of *i.v.* Mamb-1 treatment on chronification of cephalic and extra-cephalic mechanical allodynia in the rat ISDN-induced model of migraine.

A-D - Kinetics of the acute effects of a daily *i.v.* injection of Mamb-1 (11.3 nmole/kg, A, B) or vehicle (C, D) 30 min before each daily ISDN injection (10 mg/kg) on face (A, C) and paw (B, D) mechanical withdrawal threshold (g). Mean ± SEM, n = 9. * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to vehicle. # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to baseline value before any injection. E, F - Kinetics of the chronic effects of a daily *i.v.* injection of Mamb-1 or vehicle (same conditions as in A-D) on basal face (E) and paw (F) mechanical withdrawal force threshold (g) measured on the same rats before each daily injections and after the last fourth ISDN injection (day 5). Mean ± SEM, n = 9. * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to vehicle, # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to control before injection.

Fig.6: Reversion of ISDN-induced maximal extra-cephalic chronic mechanical allodynia by an intravenous injection of mambalgin-1 in wild-type and ASIC1a knock-out mice.

A, C - Kinetics of the effects of the first ISDN injection on day 1 and of the fourth ISDN injection on day 4 on hindpaw mechanical withdrawal threshold (g) of wild-type (A, n=20) and ASIC1a-KO (C, n=17) mice. Mean ± SEM, # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to control value before the ISDN injection. B, D - Kinetics of the anti-allodynic effect of Mamb-1 (13.6 nmole/kg) and vehicle *i.v.* injected one day after the last ISDN injection (*i.e.*, on day 5) on paw mechanical withdrawal force (g) of wild-type (B, n=10) and ASIC1a-KO (D, n=8-9) mice. The basal mechanical withdrawal force (g) was measured before each daily ISDN injection (left side of the y axe), showing the chronification process of cutaneous allodynia day after day. Mean ± SEM, n = 8-10. * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to vehicle; # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to control value before the first ISDN injection (day 1). Mice used in A and C have been then divided in half to be injected with either vehicle or Mamb-1, as shown in B and D.

Appendices: Supplementary figure legends

Supplementary Fig. 1: Absence of effect of intravenous and local intraplantar injections of mambalgin-1 on paw mechanical sensitivity of naive rats.

A, B - Effect of *i.v.* (A) and *i.pl.* (B) Mamb-1 on paw mechanical sensitivity. Paw mechanical withdrawal force (g), mean ± SEM, n=7-14, * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney
non parametric test compared to vehicle. C, -Total effect of i.v. and of i.pl. Mamb-1 on paw mechanical withdrawal force calculated as the Area Under Curve (AUC) during 2 hours after the injection. Mean ± SEM, * p<0.05, ** p<0.01, *** p<0.001, ns not significant compared to vehicle with Mann Whitney non parametric test.

Supplementary Fig. 2: Migraine-like, ISDN-induced cephalic and extra-cephalic acute and chronic mechanical allodynia.

A, B - Left panels - Kinetics of the effects of each of the four consecutive daily i.p. injections of the ISDN (10 mg/kg) or of saline control on the face mechanical withdrawal threshold measured with von Frey filaments (A) and on the hindpaw mechanical withdrawal threshold measured with dynamic plantar aesthesiometer (B) on the same rats. Mean ± SEM, n = 6 for saline and n= 25 for ISDN (this n number is explained by the expected high variability and small size effect in the absence of preliminary data on this ISDN-induced effects in rat). * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to saline control, # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to basal value before injection.

Right panels - Total effect on the same rats of each injection on face (A) and paw (B) withdrawal force calculated as the Area Under Curve (AUC) during 3 hours after the injection. Mean ± SEM, * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to saline control. C, D - Basal mechanical face (C) and paw (D) withdrawal force threshold (g) measured on the same rats before each daily injection (showing the settlement of chronic allodynia) and after the last fourth injection (showing the sustained effect and progressive recovery). Mean ± SEM, * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to saline control, # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to control before the first injection.

Supplementary Fig. 3: Absence of effect of intraplantar injection of mambalgin-1 on ISDN-induced cephalic and extra-cephalic chronic mechanical allodynia.

Kinetics of the effect of the local i.pl. injection of Mamb-1 (6.7 nmole/kg) one day after the last ISDN injection (i.e., on day 5) on face (A) and paw (B) mechanical withdrawal force (g) measured on the same rats (n=9). The basal mechanical withdrawal force (g) was measured before each daily ISDN injection (left side of the y axe), showing the chronification process of cutaneous allodynia day after day. Mamb-1 effect was not significantly different (p>0.05) from vehicle (Mann Whitney non parametric test).
Suppl. Fig. 4: Mambalgin-1 does not inhibit the epithelial sodium channel.
cDNAs of the α, β and γ subunits of the epithelial sodium channel (ENaC, 10 ng/µl each), were co-injected into *Xenopus* oocytes (oocytes preparation and cDNA injections as previously described (Besson *et al.*, 2017)), and oocytes were kept during two days at 19°C in ND96 solution where Na⁺ has been replaced by NMDG.

**A**, Original traces of ENaC current recorded in Na⁺-containing ND96 during voltage-steps from 0 to -80 mV every 10 s, in control condition and after application of either Mamb-1 (3µM, a concentration that inhibits ASIC channels by 70 to 100% (Diochot *et al.*, 2012)) or amiloride (10µM). Dotted line: zero current level. **B**, ENaC current (% of control current amplitude) was blocked by amiloride as expected (inhibition of 77 ± 5%) but was not inhibited by Mamb-1 (2 ± 0.9%). Mean ± SEM, n=8, **p<0.01 with Wilcoxon matched paired non parametric test.**
**A** Paw withdrawal force (g) shown for Mamb-1 and Vehicle groups. The graphs indicate a significant increase in paw withdrawal force over time after i.v. injection for Mamb-1 compared to the Vehicle group.

**B** Paw withdrawal latency (s) for Mamb-1 and Vehicle groups. The latency decreases over time after i.v. injection, with Mamb-1 showing significantly shorter latency compared to the Vehicle group.

**C** Paw withdrawal force (g) for Mamb-1 and Vehicle groups following i.pl. injection. A similar trend is observed as in i.v. injection, with Mamb-1 showing a significant increase in paw withdrawal force.

**D** Paw withdrawal latency (s) for Mamb-1 and Vehicle groups following i.pl. injection. Mamb-1 again shows a significant decrease in latency compared to the Vehicle group.

**E** Total effect on paw withdrawal force (AUC 2h) for Mamb-1 and Vehicle groups after i.v. injection. Mamb-1 shows a significantly higher total effect on paw withdrawal force compared to the Vehicle group.

**F** Total effect on paw withdrawal latency (AUC 2h) for Mamb-1 and Vehicle groups after i.pl. injection. Mamb-1 again shows a significantly lower total effect on paw withdrawal latency compared to the Vehicle group.
A

Paw withdrawal force (g)

Time after i.v. injection (min)

Mamb-1
Vehicle

B

Paw withdrawal force (g)

Time after i.pl. injection (min)

Mamb-1
Vehicle

C

Total effect on paw withdrawal force (AUC 2h)

Vehicle i.v.
Mamb-1 i.v.
Vehicle i.pl.
Mamb-1 i.pl.

ns
ns
A

Face withdrawal force (g)

- ISDN IP1
- Saline IP1
- ISDN IP2
- Saline IP2
- ISDN IP3
- Saline IP3
- ISDN IP4
- Saline IP4

Time after i.p. injection (min)

Total effect of i.p. injection on face withdrawal force (AUC 3h)

B

Paw withdrawal force (g)

- ISDN IP1
- Saline IP1
- ISDN IP2
- Saline IP2
- ISDN IP3
- Saline IP3
- ISDN IP4
- Saline IP4

Time after i.p. injection (min)

Total effect of i.p. injection on paw withdrawal force (AUC 3h)

C

Face withdrawal force (g)

- ISDN
- Saline

Time (days)

IP1 IP2 IP3 IP4

D

Paw withdrawal force (g)

- ISDN
- Saline

Time (days)

IP1 IP2 IP3 IP4

British Pharmacological Society
A

ENaC current Inhibition (% control amplitude)

-80 mV

0 mV

200 nA

100 ms

Mamb-1 Amiloride

control

B

ENaC current Inhibition (% control amplitude)

Mamb-1

Amiloride

**

British Pharmacological Society